Cefpodoxime Proxetil

CHEMBL1201016 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
557.6 g/mol
LogP
0.6
Phase
4

An oral third-generation cephalosporin prodrug that is de-esterified in the intestinal wall to the active compound cefpodoxime. It provides broad-spectrum activity against common respiratory pathogens and is used for ear, throat, sinus, and urinary tract infections. Food enhances its absorption, and it should be taken with meals for optimal effect.

आणविक भार

557.6000 g/mol

LogP

0.60

TPSA

235.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

क्रिया का तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCC1=C(C(=O)OC(C)OC(=O)OC(C)C)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1

InChI

InChI=1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

Molecular Formula

C21H27N5O9S2

HBD / HBA

2 / 14

घूर्णनीय बंधन

13

भारी परमाणु

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An oral third-generation cephalosporin prodrug that is de-esterified in the intestinal wall to the active compound cefpodoxime. It provides broad-spectrum activity against common respiratory pathogens and is used for ear, throat, sinus, and urinary tract infections. Food enhances its absorption, and it should be taken with meals for optimal effect.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefpodoxime Proxetil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201016. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6526396. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.